염증성 장질환 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 약물 종류별, 투여 경로별, 유통 경로별, 지역별, 부문별 예측(2024-2030년)

Inflammatory Bowel Disease Treatment Market Growth & Trends:

The global inflammatory bowel disease treatment market size is expected to reach USD 27.73 billion by 2030, expanding at a CAGR of 3.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of the disease, the surge in awareness about inflammatory bowel disease among people, and favorable regulatory scenarios are projected to drive the inflammatory bowel disease treatment market over the forecast period. For instance, in December 2022, Pfizer Inc. announced the U.S. FDA acceptance for review of an NDA for etrasimod for patients having severe ulcerative colitis. The favorable initiatives undertaken by regulatory authorities for treatment designations and approval of novel drugs for the management of inflammatory bowel disease are fueling market expansion.

The increasing collaboration of market players and non-profit organizations to counter various challenges in the development of novel therapeutics for IBD treatment is projected to propel market growth. For instance, in October 2022, Verily, a precision health company and the Crohn's & Colitis Foundation expanded their strategic collaboration to accelerate research in ulcerative colitis and Crohn's disease. In addition, the European Crohn's and Colitis Organization has taken several favorable steps to improve the care of patients living with inflammatory bowel disease.

Recently approved novel drugs such as filgotinib, ozanimod, upadacitinib, and risankizumab for the treatment of inflammatory bowel disease are expected to support market growth in the coming years. Moreover, the regulatory authorities are encouraging manufacturers to develop novel therapeutic approaches for rare and life-threatening diseases. For instance, in December 2020, Thetis Pharmaceuticals received an orphan drug designation for TP-317 from the U.S. FDA for pediatric ulcerative colitis. Such favorable initiatives are expected to boost the R&D activities to develop novel therapeutic products for IBD.

Furthermore, the rising demand & approvals for biosimilars for the treatment of various inflammatory conditions is a high-impact rendering factor for the market. For instance, in December 2022, the U.S. FDA approved Idacio as an eighth adalimumab biosimilar in the U.S. The newly approved biosimilar is a citrate-free low-concentration preparation intended for the treatment of several inflammatory conditions, including CD in adults and children aged 6 years or older. In addition, in October 2021, the U.S. FDA approved Cyltezo for the management of moderate to severe CD and UC. Moreover, the increasing introduction of biosimilars is expected to boost the adoption of biological products for the treatment of IBD in developing economies.

Moreover, government bodies are taking efforts to promote the uptake of biosimilars with their safe use. For instance, in October 2022, the government of Saskatchewan launched a biosimilar initiative to help its residents to access high-quality therapeutics at a lesser cost. Similarly, provinces like Ontario and Quebec in Canada are also expanding biosimilar initiatives to promote the uptake of biosimilar candidates.

Inflammatory Bowel Disease Market Report Highlights:

• The Crohn's disease segment held the largest share owing to the increasing prevalence of the condition and the high prescription rate of biologics for the treatment of the disease
• The ulcerative colitis segment is poised to register the fastest growth rate due to the rising approval of biologics for the treatment of ulcerative colitis and the high patient base
• The TNF inhibitors segment accounted for the largest market share in 2023 owing to the high prescription rate for the treatment of IBD and rising consumer awareness about TNF inhibitors
• Based on the route of administration, the injectable segment dominated the inflammatory bowel disease treatment market in 2023, whereas the oral segment is anticipated to be the fastest-growing segment
• The hospital pharmacy segment was the largest in 2023, owing to higher hospitalization rates and favorable reimbursement coverage
• Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the rising investments by market players and increasing disease prevalence in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
• 1.7. Details of primary research
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.1.1. Approach 1: Commodity flow approach
  • 1.9.2. Volume price analysis (Model 2)
    • 1.9.2.1. Approach 2: Volume price analysis
• 1.10. Research Scope and Assumptions
  • 1.10.1. List of Secondary Sources
  • 1.10.2. List of Primary Sources
  • 1.10.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Robust product pipeline
    • 3.2.1.2. High prevalence of Crohn's disease and ulcerative colitis
    • 3.2.1.3. Increasing geriatric population
    • 3.2.1.4. Emergence of biosimilars
    • 3.2.1.5. Support of regulatory bodies for funding and designation
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Lack of early diagnosis
• 3.3. Inflammatory Bowel Disease Treatment Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Legal landscape
• 3.4. List of Main Products & Average Selling Price

Chapter 4. Inflammatory Bowel Disease Treatment Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Inflammatory Bowel Disease Treatment Market: Type Movement Analysis, USD Billion, 2023 & 2030
• 4.3. Crohn's Disease
  • 4.3.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4. Ulcerative Colitis
  • 4.4.1. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Inflammatory Bowel Disease Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Inflammatory Bowel Disease Treatment Market: Drug Class Movement Analysis, USD Billion, 2023 & 2030
• 5.3. Aminosalicylates
  • 5.3.1. Aminosalicylates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Corticosteroids
  • 5.4.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. TNF Inhibitors
  • 5.5.1. TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. IL Inhibitors
  • 5.6.1. IL Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Anti-integrin
  • 5.7.1. Anti-integrin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. JAK Inhibitors
  • 5.8.1. JAK Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Inflammatory Bowel Disease Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Inflammatory Bowel Disease Treatment Market: Route of Administration Movement Analysis, USD Billion, 2023 & 2030
• 6.3. Oral
  • 6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Injectable
  • 6.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Inflammatory Bowel Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Inflammatory Bowel Disease Treatment Market: Distribution Channel Movement Analysis, USD Billion, 2023 & 2030
• 7.3. Hospital Pharmacy
  • 7.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Retail Pharmacy
  • 7.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Online Pharmacy
  • 7.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Inflammatory Bowel Disease Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Inflammatory Bowel Disease Treatment Market Share, By Region, 2023 & 2030, USD Billion
• 8.2. North America
  • 8.2.1. North America Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.2.2.3. Competitive Insights
    • 8.2.2.4. U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.2.3.3. Competitive Insights
    • 8.2.3.4. Canada Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.3. Europe
  • 8.3.1. Europe Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.2.3. Competitive Insights
    • 8.3.2.4. Germany Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.3.3. Competitive Insights
    • 8.3.3.4. UK Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.4. Spain
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.4.3. Competitive Insights
    • 8.3.4.4. Spain Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.5. France
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.5.3. Competitive Insights
    • 8.3.5.4. France Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.6. Italy
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.6.3. Competitive Insights
    • 8.3.6.4. Italy Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.7.3. Competitive Insights
    • 8.3.7.4. Denmark Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.8.3. Competitive Insights
    • 8.3.8.4. Sweden Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Regulatory Landscape/Reimbursement Scenario
    • 8.3.9.3. Competitive Insights
    • 8.3.9.4. Norway Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. Japan Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. China Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. India Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.5.3. Competitive Insights
    • 8.4.5.4. South Korea Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.6.3. Competitive Insights
    • 8.4.6.4. Australia Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.7. Singapore
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.7.3. Competitive Insights
    • 8.4.7.4. Singapore Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Regulatory Landscape/Reimbursement Scenario
    • 8.4.8.3. Competitive Insights
    • 8.4.8.4. Thailand Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.5. Latin America
  • 8.5.1. Latin America Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. Brazil Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Mexico Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. Argentina Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. South Africa Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. Saudi Arabia Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. UAE Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. Kuwait Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Market Share Analysis, 2023
• 9.4. Strategy Mapping
  • 9.4.1. Expansion
  • 9.4.2. Mergers & Acquisition
  • 9.4.3. Partnerships & Collaborations
  • 9.4.4. New Product Launches
  • 9.4.5. Research And Development
• 9.5. Company Profiles
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Participant's Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Recent Developments
  • 9.5.2. Takeda Pharmaceutical Company Limited
    • 9.5.2.1. Participant's Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Recent Developments
  • 9.5.3. Pfizer Inc.
    • 9.5.3.1. Participant's Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Recent Developments
  • 9.5.4. Biogen
    • 9.5.4.1. Participant's Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Recent Developments
  • 9.5.5. Novartis AG
    • 9.5.5.1. Participant's Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Recent Developments
  • 9.5.6. Lilly
    • 9.5.6.1. Participant's Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Recent Developments
  • 9.5.7. UCB S.A.
    • 9.5.7.1. Participant's Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Recent Developments
  • 9.5.8. CELLTRION INC.
    • 9.5.8.1. Participant's Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Recent Developments
  • 9.5.9. Merck & Co., Inc.
    • 9.5.9.1. Participant's Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Recent Developments
  • 9.5.10. Johnson & Johnson Services, Inc
    • 9.5.10.1. Participant's Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Recent Developments